MedPath

PAUL T. FINGER M.D. P.C.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:3

Trial Phases

1 Phases

Phase 1:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
3 (100.0%)

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

Phase 1
Completed
Conditions
Radiation Retinopathy
Interventions
First Posted Date
2011-04-13
Last Posted Date
2014-10-02
Lead Sponsor
The New York Eye Cancer Center
Target Recruit Count
10
Registration Number
NCT01334879
Locations
🇺🇸

The New York Eye Cancer Center, New York, New York, United States

Effect of Intravitreal Ranibizumab on Radiation Retinopathy Following Plaque Brachytherapy for Choroidal Melanoma

Phase 1
Completed
Conditions
Radiation Retinopathy
Choroidal Melanoma
Interventions
First Posted Date
2008-09-10
Last Posted Date
2012-04-26
Lead Sponsor
The New York Eye Cancer Center
Target Recruit Count
10
Registration Number
NCT00750399
Locations
🇺🇸

The New York Eye Cancer Center, New York, New York, United States

Effect of Ranibizumab on Malignant Conjunctival Neoplasia

Phase 1
Completed
Conditions
Conjunctival Neoplasms
Interventions
First Posted Date
2007-04-05
Last Posted Date
2017-07-21
Lead Sponsor
The New York Eye Cancer Center
Target Recruit Count
5
Registration Number
NCT00456495
Locations
🇺🇸

The New York Eye Cancer Center, New York, New York, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.